Skip to main content
Premium Trial:

Request an Annual Quote

To Plead Guilty

Representative Chris Collins (R-NY) has resigned his seat in the US House of Representatives and is to plead guilty this afternoon to insider trading charges, the Washington Post reports.

It adds that Collins allegedly tipped off his son about confidential information he learned as a member of the board and largest shareholder of the Australian biotechnology firm Innate Immunotherapeutics, enabling him and others to avoid a loss totaling more than $700,000. According to the Post, Collins was at a congressional picnic when he learned that a drug trial Innate was conducting had failed, which led him to contact his son, who held millions of shares in the company.

"Collins, who, by virtue of his office, helps write the laws of this country, acted as if the law did not apply to him," US Attorney Geoffrey Berman said, according to Vox, following Collins's 2018 arrest. Vox adds that Collins had urged other lawmakers to invest in the company.

The Post notes that it is unclear whether Collins plans to plead guilty to all or just some of the charges against him, which include securities and wire fraud as well as lying to the Federal Bureau of Investigations. Collins's son and another family member are also to plead guilty later this week, it adds.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.